Evogene (NASDAQ:EVGN) Price Target Cut to $7.00

Evogene (NASDAQ:EVGN) had its price objective trimmed by Royal Bank of Canada from $8.00 to $7.00 in a research report report published on Wednesday morning, Stock Target Advisor reports. The firm currently has an outperform rating on the biotechnology company’s stock.

EVGN has been the subject of a number of other research reports. Roth Capital began coverage on Evogene in a research note on Friday, October 8th. They issued a buy rating and a $7.00 price objective for the company. Zacks Investment Research downgraded shares of Evogene from a hold rating to a sell rating in a research report on Monday. Finally, Aegis began coverage on shares of Evogene in a research note on Thursday, July 29th. They set a buy rating and a $10.00 price target for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $7.30.

Shares of EVGN opened at $2.02 on Wednesday. Evogene has a 1-year low of $1.90 and a 1-year high of $10.24. The stock has a market cap of $52.02 million, a PE ratio of -2.66 and a beta of 1.23. The firm has a fifty day moving average price of $2.60 and a 200 day moving average price of $3.00.

Evogene (NASDAQ:EVGN) last posted its earnings results on Tuesday, November 16th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.02). Evogene had a negative return on equity of 40.83% and a negative net margin of 3,013.61%. During the same period last year, the firm posted ($0.17) EPS. On average, analysts anticipate that Evogene will post -0.71 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN increased its holdings in shares of Evogene by 164.9% in the second quarter. Wells Fargo & Company MN now owns 7,946 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 4,946 shares during the period. SNS Financial Group LLC purchased a new position in Evogene in the 2nd quarter valued at $34,000. Citigroup Inc. acquired a new position in Evogene in the 1st quarter valued at $34,000. Crestwood Advisors Group LLC acquired a new position in Evogene in the 3rd quarter valued at $37,000. Finally, XTX Topco Ltd purchased a new position in Evogene during the 2nd quarter worth $72,000. Institutional investors own 28.77% of the company’s stock.

Evogene Company Profile

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agrobiological products to improve plant performance.

Featured Story: Why do company’s buyback their stock?

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.